Key Takeaways
- Oscar Health (OSCR) shares surged approximately 11% on Wednesday following CEO Mark Bertolini’s acquisition of 1 million shares at $11.92 each.
- The $11.92M deal was structured as a private placement, with new shares issued directly to the executive rather than purchased on the open market.
- Bertolini’s holdings now total 10.2M shares, giving him a 10.87% ownership position in the health insurance company.
- The stock had previously gained around 7% on Tuesday when the federal government announced a 2.5% increase in Medicare Advantage reimbursement rates for 2027.
- Despite posting $443.2M in net losses for 2025, Oscar is projecting 60% revenue expansion in 2026, with targets between $18.7B and $19B.
Oscar Health (OSCR) is currently trading at $14.43, reflecting a $2.21 increase (+15.29%) at the market opening.
Mark Bertolini, CEO of Oscar Health, captured investor attention this week with a substantial 1 million share acquisition at $11.92 per share — representing a $11.92M commitment to the health insurance company’s future. Wednesday morning saw the stock surge roughly 11% following the announcement.
A regulatory disclosure filed after Tuesday’s market close revealed the transaction, which took place on Monday, April 6. Bertolini, who formerly led Aetna as CEO, executed the purchase through a structured arrangement.
However, this wasn’t a standard market transaction. According to the SEC Form 4 filing, the deal was executed as a private placement — Oscar created and issued 1 million fresh shares directly to the CEO at the $11.92 closing price, matching the valuation used that day for tax withholding on performance units that had vested.
This arrangement injected $11.92M in new funding into Oscar’s treasury while expanding Bertolini’s position to 10,196,876 shares, representing 10.87% ownership. The dilutive impact on existing shareholders remained relatively modest.
Financial Performance Overview
Oscar’s 2025 financial results reveal a company experiencing rapid expansion while still operating at a loss. Annual revenue reached $11.7B, compared to $9.18B the previous year. The company’s membership base hit an all-time high of 3.4 million people. However, net losses totaled $443.2M for the year, with operational losses at $396.4M.
Looking ahead to 2026, management is forecasting revenue between $18.7B and $19B — representing approximately 60% year-over-year expansion — while aiming for a medical-loss ratio ranging from 82.4% to 83.4%. Wall Street analysts anticipate EPS of $0.77 for 2026, which would signal the company’s shift into profitable territory.
Reaching these ambitious goals won’t be easy. But Bertolini’s substantial personal investment indicates his confidence in achieving them.
For context, established industry players show different growth trajectories: UnitedHealth Group reported Q4 2025 revenue of $113.2B, representing 12.3% year-over-year growth. Meanwhile, Centene and Molina Healthcare expanded at single-digit rates. Oscar’s growth velocity stands apart, though profitability remains elusive.
Understanding the Transaction Structure
It’s important to recognize what distinguishes this transaction from typical insider purchases. A conventional open-market buy — where an executive purchases shares at market price, accepting potential immediate losses and market volatility — generally sends a stronger conviction signal. Such purchases communicate: “I believe in this valuation right now.”
A private placement operates differently. Bertolini didn’t simply place a market order. He received newly issued shares at a predetermined fair market value as part of a structured transaction connected to equity vesting. The company gained capital; the CEO increased his ownership.
That said, Bertolini had the option to liquidate vested shares for tax obligations and pocket the proceeds. Instead, he chose to expand his holdings. At today’s valuation, his Oscar position is worth approximately $125M.
OSCR shares had already appreciated roughly 7% on Tuesday after federal officials confirmed a 2.5% Medicare Advantage reimbursement rate increase for 2027 — exceeding the initial proposal that would have maintained flat rates.
Oscar’s Q1 2025 earnings report is set for release on May 6 during pre-market hours.
